Abstract

This is a retrospective research of 50 cases that uses immunohistochemistry to assess the expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor proliferation index in breast carcinomas. The purpose of this research was to apply molecular categorization to patient data, examine how that data compared to clinicopathological factors, and highlight the value of targeted therapy. Materials and Methods: Specimens from April 2023 to July 2023 were collected at the tertiary care center in Telangana for analysis of the expression of the aforementioned markers following modified radical mastectomy. Infiltrating ductal carcinoma of undifferentiated type and its variants including medullary, papillary, metaplastic, lobular, mucinous, and apocrine carcinoma were identified in Hematoxylin. Fifty samples were chosen for immunohistochemistry investigation, thirty of which were IDC NST and thirty of which were unique variations. Results: Among the 50 instances analyzed, 37% were determined to be of the luminal A type, while 8% each were of the luminal B and hybrid types. Grade III HER2 was the most common grade. Forty-eight percent of the 50 cases were considered successful. The HER2, Hybrid, and Basal subtypes each accounted for one death. When comparing the agreement between histopathological and molecular classification, a negative kappa value shows that the agreement is poorer than chance, lending credence to the necessity of molecular classification for targeted therapy. Conclusion: Molecular subgroup research would open the way for "personalization" of treatment for breast tumors using the more practical and cost-effective technology of immunohistochemistry, which is important because breast cancers are heterogeneous and have varying clinical outcomes.

Description